“…Both these technologies can be applied to analyze either a predefined subset of metabolites, structurally related or associated with a certain metabolic pathway -targeted metabolomics, or the entire set of metabolites -untargeted global metabolomics (Figure 24.8). 261,[319][320][321] Advanced NMR-and MS-based technologies have been initiated to use in profiling metabolomic changes associated with various CVD ranging from atherosclerosis, AF, and diabetes mellitus to pulmonary hypertension, MI, and HF. 319,320,[322][323][324] Several noninvasive, 1 H-NMR-based metabolomic studies have been applied to assess the severity of CAD; however, they have reached the conclusion that this approach is poor for predicting disease risk compared to standard angiography or clinical measurements of lipids and lipoproteins.…”